Search research articles
Contact Us
Filters
Showing results (11-20 of 26) with videos related to
Page
of 3
Sort By:
The New England Journal of Medicine
|
March 23, 1972
Treatment of essential hypertension with combined vasodilation and beta-adrenergic blockade
R Zacest, E Gilmore, J Koch-Weser
Journal of Chromatography
|
March 14, 1980
Selective high-performance liquid chromatographic assays for hydralazine and its metabolites in plasma of man
P A Reece, I Cozamanis, R Zacest
European Journal of Clinical Pharmacology
|
January 1, 1982
Influence of acetylator phenotype on the pharmacokinetics of a new vasodilator antihypertensive, endralazine
P A Reece, I Cozamanis, R Zacest
European Journal of Clinical Pharmacology
|
January 1, 1983
Endralazine - a new hydralazine-like antihypertensive with high systemic bioavailability
P A Reece, I Cozamanis, R Zacest
Journal of Chromatography
|
September 11, 1981
Sensitive high-performance liquid chromatographic assay for endralazine and two of its metabolites in human plasma
P A Reece, I Cozamanis, R Zacest
Journal of Chromatography
|
July 21, 1979
Quantification of imipramine and desipramine in plasma by high-performance liquid chromatography and fluorescence detection
P A Reece, R Zacest, C G Barrow
Journal of Pharmaceutical Sciences
|
August 1, 1978
Interference in assays for hydralazine in humans by a major plasma metabolite, hydralazine pyruvic acid hydrazone
P A Reece, P E Stanley, R Zacest
European Journal of Clinical Pharmacology
|
January 3, 1977
The ambiguity of adverse drug reactions
J Koch-Weser, E M Sellers, R Zacest
The Medical Journal of Australia
|
January 9, 1982
Hypersensitivity reaction to Depo-Provera
R Zacest, A Cushway, C Haines, et al.
Lancet (London, England)
|
December 15, 1979
Suspiciousness trait: a factor in antihypertensive drug trials
M W O'Halloran, R Zacest, C G Barrow, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 26) with videos related to
Sort By:
Page
of 3
The New England Journal of Medicine
|
March 23, 1972
Treatment of essential hypertension with combined vasodilation and beta-adrenergic blockade
R Zacest, E Gilmore, J Koch-Weser
Journal of Chromatography
|
March 14, 1980
Selective high-performance liquid chromatographic assays for hydralazine and its metabolites in plasma of man
P A Reece, I Cozamanis, R Zacest
European Journal of Clinical Pharmacology
|
January 1, 1982
Influence of acetylator phenotype on the pharmacokinetics of a new vasodilator antihypertensive, endralazine
P A Reece, I Cozamanis, R Zacest
European Journal of Clinical Pharmacology
|
January 1, 1983
Endralazine - a new hydralazine-like antihypertensive with high systemic bioavailability
P A Reece, I Cozamanis, R Zacest
Journal of Chromatography
|
September 11, 1981
Sensitive high-performance liquid chromatographic assay for endralazine and two of its metabolites in human plasma
P A Reece, I Cozamanis, R Zacest
Journal of Chromatography
|
July 21, 1979
Quantification of imipramine and desipramine in plasma by high-performance liquid chromatography and fluorescence detection
P A Reece, R Zacest, C G Barrow
Journal of Pharmaceutical Sciences
|
August 1, 1978
Interference in assays for hydralazine in humans by a major plasma metabolite, hydralazine pyruvic acid hydrazone
P A Reece, P E Stanley, R Zacest
European Journal of Clinical Pharmacology
|
January 3, 1977
The ambiguity of adverse drug reactions
J Koch-Weser, E M Sellers, R Zacest
The Medical Journal of Australia
|
January 9, 1982
Hypersensitivity reaction to Depo-Provera
R Zacest, A Cushway, C Haines, et al.
Lancet (London, England)
|
December 15, 1979
Suspiciousness trait: a factor in antihypertensive drug trials
M W O'Halloran, R Zacest, C G Barrow, et al.
Page
of 3